{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T03:27:30Z","timestamp":1794886050274,"version":"4.9.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T00:00:00Z","timestamp":1660176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T00:00:00Z","timestamp":1660176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004434","name":"Universit\u00e0 degli Studi di Firenze","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004434","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiol med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\u00a0Pleomorphic xanthoastrocytoma (PXA) is a rare low-grade brain tumor. To date, limited studies have analyzed factors affecting survival outcomes and defined the therapeutic strategy. The aim of this retrospective analysis was to investigate the clinicopathologic characteristics of PXA and identify factors associated with outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\u00a0We retrospectively analyzed a cohort of 16 adult and children patients with PXA who underwent primary resection from 1997 to 2019, referred to our Radiation Oncology Unit and to Meyer\u2019s Paediatric Hospital. We also reviewed the relevant literature.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      \u00a0All patients underwent primary surgical resection; 10 patients received adjuvant radiation treatment course, ranging from DTF 54 to 64\u00a0Gy; 8 of them received, in addition, concurrent adjuvant chemotherapy; 6 patients underwent only radiological follow-up. After a median follow up was 60\u00a0months: median OS was 34.9\u00a0months (95% CI 30\u2013218), 1-year OS 87%, 5-years OS 50%, 10-years OS 50%; median PFS 24.4\u00a0months (95% CI 13\u2013156), 1-year PFS 80%, 5-years PFS 33%, 10-years PFS 33%. A chi-square test showed a significant association between OS and recurrent disease (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002) and with chemotherapy adjuvant treatment (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.049). A borderline statistical significant association was instead recognized with BRAF mutation (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.058).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Despite our analysis did not reveal a strong prognostic or predictive factor able to address pleomorphic xanthoastrocytoma management; however, in selected patients could be considered the addition of adjuvant radiation chemotherapy treatment after adequate neurosurgical primary resection. Furthermore, recurrent disease evidenced a detrimental impact on survival.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11547-022-01531-3","type":"journal-article","created":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T10:03:01Z","timestamp":1660212181000},"page":"1134-1141","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Pleomorphic Xanthoastrocytoma: a single institution retrospective analysis and a review of the literature"],"prefix":"10.1007","volume":"127","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5799-5924","authenticated-orcid":false,"given":"Beatrice","family":"Detti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Scoccianti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Maragna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Lucidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Ganovelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Ausilia","family":"Teriaca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saverio","family":"Caini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isacco","family":"Desideri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Agresti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Greto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Buccoliero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro Della","family":"Puppa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iacopo","family":"Sardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Livi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,11]]},"reference":[{"key":"1531_CR1","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","volume":"131","author":"DN Louis","year":"2016","unstructured":"Louis DN et al (2016) The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 131:803\u2013820. https:\/\/doi.org\/10.1007\/s00401-016-1545-1","journal-title":"Acta Neuropathol"},{"key":"1531_CR2","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/bpa.12639","volume":"29","author":"JJ Phillips","year":"2019","unstructured":"Phillips JJ et al (2019) The genetic landscape of anaplastic pleomorphic xanthoastrocytoma. Brain Pathol 29:85\u201396","journal-title":"Brain Pathol"},{"key":"1531_CR3","doi-asserted-by":"crossref","unstructured":"Thomas Kaley et al (2018) BRAF Inhibition in BRAFV600-mutant gliomas: results from the VE-BASKET study. J Clin Oncol 36:3477\u20133484","DOI":"10.1200\/JCO.2018.78.9990"},{"key":"1531_CR4","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s11060-012-0939-8","volume":"110","author":"M Perkins","year":"2012","unstructured":"Perkins M et al (2012) Patterns of care and outcomes of patients with pleomorphic xanthoastrocytoma: a SEER analysis. J Neurooncol 110:99\u2013104. https:\/\/doi.org\/10.1007\/s11060-012-0939-8","journal-title":"J Neurooncol"},{"key":"1531_CR5","doi-asserted-by":"crossref","unstructured":"Nawal Shaikh et al (2019) Pleomorphic xanthoastrocytoma: a brief review. CNS Oncol 8(3):CNS39.","DOI":"10.2217\/cns-2019-0009"},{"key":"1531_CR6","unstructured":"NCI. National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0. http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm. Accessed 8 Nov 2018"},{"key":"1531_CR7","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1200\/JCO.2017.72.7511","volume":"35","author":"PY Wen","year":"2017","unstructured":"Wen PY et al (2017) Response assessment in neuro-oncology clinical trials. J Clin Oncol 35:2439\u20132449. https:\/\/doi.org\/10.1200\/JCO.2017.72.7511","journal-title":"J Clin Oncol"},{"key":"1531_CR8","unstructured":"ITALIAN CANCER FIGURES\u2014report 2015 the burden of rare cancers in Italy. airtum Working Group. ANNO 40(1) (2016)"},{"issue":"5","key":"1531_CR9","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.2665","volume":"10","author":"F Roberti","year":"2018","unstructured":"Roberti F, Baggenstos M (2018) Intraventricular anaplastic pleomorphic xanthoastrocytoma: very rare localization and early recurrence of a rare tumor. Cureus 10(5):e2665. https:\/\/doi.org\/10.7759\/cureus.2665","journal-title":"Cureus"},{"key":"1531_CR10","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1111\/j.1440-1789.2009.01080.x","volume":"30","author":"Fu Yong-Juan","year":"2010","unstructured":"Yong-Juan Fu et al (2010) Intraventricular pleomorphic xanthoastrocytoma with anaplastic features. Neuropathology 30:443\u2013448. https:\/\/doi.org\/10.1111\/j.1440-1789.2009.01080.x","journal-title":"Neuropathology"},{"key":"1531_CR11","doi-asserted-by":"crossref","unstructured":"Nagaishi M et al (2020) Rare clinical presentations of pleomorphic xanthoastrocytoma with a high proliferative index: two case reports. Medicine 99:3(e18880).","DOI":"10.1097\/MD.0000000000018880"},{"key":"1531_CR12","doi-asserted-by":"publisher","unstructured":"Otluo\u011flu D et al (2019) A rare clinical presentation: a pleomorphic xanthoastrocytoma presenting with intracerebral haemorrhage and metastasizing vigorously\u2014case report and review of the literature. Child's Nervous System. https:\/\/doi.org\/10.1007\/s00381-018-3960-1","DOI":"10.1007\/s00381-018-3960-1"},{"key":"1531_CR13","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s00381-003-0854-6","volume":"20","author":"A Lubansu","year":"2004","unstructured":"Lubansu A et al (2004) Cerebral anaplastic pleomorphic xanthoastrocytoma with meningeal dissemination at first presentation. Childs Nerv Syst 20:119\u2013122. https:\/\/doi.org\/10.1007\/s00381-003-0854-6","journal-title":"Childs Nerv Syst"},{"issue":"4","key":"1531_CR14","first-page":"1118","volume":"12","author":"X-F Liu","year":"2019","unstructured":"Liu X-F et al (2019) Pleomorphic xanthoastrocytoma inside lateral ventricle: a rare case report and literature review. Int J Clin Exp Pathol 12(4):1118\u20131123","journal-title":"Int J Clin Exp Pathol"},{"key":"1531_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2018.05.003","author":"S Mallick","year":"2018","unstructured":"Mallick S et al (2018) Grade II Pleomorphic Xanthoastrocytoma; a meta-analysis of data from previously reported 167 cases. J Clin Neurosci. https:\/\/doi.org\/10.1016\/j.jocn.2018.05.003","journal-title":"J Clin Neurosci"},{"key":"1531_CR16","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1055\/s-0039-1697873","volume":"10","author":"S Mallick","year":"2019","unstructured":"Mallick S et al (2019) Demography, pattern of care, and survival in patients with xanthoastrocytoma: a systematic review and individual patient data analysis of 325 Cases. J Neurosci Rural Pract 10:430\u2013437","journal-title":"J Neurosci Rural Pract"},{"key":"1531_CR17","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1002\/pbc.22490","volume":"55","author":"Rao","year":"2010","unstructured":"Rao et al (2010) Pleomorphic Xanthoastrocytoma in children and adolescents. Pediatr Blood Cancer 55:290\u2013294","journal-title":"Pediatr Blood Cancer"},{"key":"1531_CR18","first-page":"1839","volume":"5445","author":"JJ Jhon Kepe","year":"1979","unstructured":"Jhon Kepe JJ et al (1979) Pleomorphic xanthoastrocytoma: a distinctive meningocerebral glioma of young subjects with relatively favorable prognosis. A study of 12 cases. Cancer 44:1839\u20131852.","journal-title":"Cancer"},{"key":"1531_CR19","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1002\/(SICI)1097-0142(19990501)85:9<2033::AID-CNCR22>3.0.CO;2-Z","volume":"85","author":"C Giannini","year":"1999","unstructured":"Giannini C et al (1999) Pleomorphic xanthoastrocytoma What do we really know about it? Cancer 85:2033\u20132045","journal-title":"Cancer"},{"key":"1531_CR20","doi-asserted-by":"publisher","DOI":"10.3109\/02688697.2013.776666","author":"P Gallo","year":"2013","unstructured":"Gallo P et al (2013) Pleomorphic xanthoastrocytoma: long-term results of surgical treatment and analysis of prognostic factors. British Neurosurg. https:\/\/doi.org\/10.3109\/02688697.2013.776666","journal-title":"British Neurosurg"},{"key":"1531_CR21","doi-asserted-by":"publisher","unstructured":"Ida CM et al (2015) Pleomorphic Xanthoastrocytoma: natural history and long-term follow-up. Brain Pathol 25(5):575\u2013586. https:\/\/doi.org\/10.1111\/bpa.12217","DOI":"10.1111\/bpa.12217"},{"key":"1531_CR22","doi-asserted-by":"crossref","unstructured":"Pradhan P et al (2018) Clinico-histomorphological and immunohistochemical profile of anaplastic pleomorphic xanthoastrocytoma: report of five cases and review of literature IJHOSCR, 1 October 2018. Volume 12, Number 4","DOI":"10.18502\/ijhoscr.v12i4.104"},{"key":"1531_CR23","doi-asserted-by":"publisher","unstructured":"Yan J et al (2018) Pleomorphic xanthoastrocytomas of adults: MRI features, molecular markers, and clinical outcomes. Scientific RePortS 8:14275. https:\/\/doi.org\/10.1038\/s41598-018-32273-w","DOI":"10.1038\/s41598-018-32273-w"},{"key":"1531_CR24","doi-asserted-by":"publisher","first-page":"512","DOI":"10.3171\/2018.11.PEDS18449","volume":"23","author":"T Lundar","year":"2019","unstructured":"Lundar T et al (2019) Neurosurgical treatment of pediatric pleomorphic xanthoastrocytomas: long-term follow-up of a single-institution, consecutive series of 12 patients. J Neurosurg Pediatr 23:512\u2013516","journal-title":"J Neurosurg Pediatr"},{"key":"1531_CR25","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s11060-013-1176-5","volume":"114","author":"MC Chamberlain","year":"2013","unstructured":"Chamberlain MC (2013) Salvage therapy with BRAF inhibitors for recurrent pleomorphic xanthoastrocytoma: a retrospective case series. J Neuroncol 114:237\u2013240. https:\/\/doi.org\/10.1007\/s11060-013-1176-5","journal-title":"J Neuroncol"},{"key":"1531_CR26","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s00415-019-09575-8","volume":"267","author":"Pi\u00f1a","year":"2020","unstructured":"Pi\u00f1a et al (2020) Using personalized medicine in gliomas: a genomic approach to diagnosis and overcoming treatment resistance in a case with pleomorphic xanthoastrocytoma. J Neurol 267:783\u2013790. https:\/\/doi.org\/10.1007\/s00415-019-09575-8","journal-title":"J Neurol"},{"key":"1531_CR27","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s00401-011-0802-6","volume":"121","author":"G Schindler","year":"2011","unstructured":"Schindler G et al (2011) Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 121:397\u2013405. https:\/\/doi.org\/10.1007\/s00401-011-0802-6","journal-title":"Acta Neuropathol"},{"key":"1531_CR28","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/bpa.12111","volume":"24","author":"C Koelsche","year":"2014","unstructured":"Koelsche C et al (2014) BRAF-Mutated Pleomorphic Xanthoastrocytoma is associated with temporal location, reticulin fiber deposition and CD34 expression. Brain Pathol 24:221\u2013229","journal-title":"Brain Pathol"},{"key":"1531_CR29","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1097\/MPH.0000000000001395","volume":"42","author":"EA Finch","year":"2020","unstructured":"Finch EA et al (2020) Long-term efficacy of single-agent vemurafenib for Pleomorphic Xanthoastrocytoma. J Pediatr Hematol Oncol 42:152\u2013155","journal-title":"J Pediatr Hematol Oncol"},{"key":"1531_CR30","doi-asserted-by":"publisher","unstructured":"Petruzzellis G et al (2019) Vemurafenib treatment of Pleomorphic Xanthoastrocytoma in a child with Down Syndrome. Front Oncol 9:277. https:\/\/doi.org\/10.3389\/fonc.2019.00277","DOI":"10.3389\/fonc.2019.00277"},{"key":"1531_CR31","doi-asserted-by":"crossref","unstructured":"Rimas V Lukas, Ryan T Merrell (2018) BRAF inhibition with concomitant tumor treating fields for a multiply progressive pleomorphic xanthoastrocytoma. CNS Oncol.","DOI":"10.2217\/cns-2017-0032"},{"issue":"10","key":"1531_CR32","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1097\/NEN.0000000000000240","volume":"74","author":"A Usubalieva","year":"2015","unstructured":"Usubalieva A et al (2015) Primary Meningeal Pleomorphic Xanthoastrocytoma with anaplastic features: a report of 2 cases, one with BRAFV600E mutation and clinical response to the BRAF Inhibitor Dabrafenib. J Neuropathol Exp Neurol 74(10):960\u2013969. https:\/\/doi.org\/10.1097\/NEN.0000000000000240","journal-title":"J Neuropathol Exp Neurol"},{"key":"1531_CR33","unstructured":"https:\/\/clinicaltrials.gov\/"},{"key":"1531_CR34","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.wneu.2018.12.095)","volume":"126","author":"Hosono","year":"2019","unstructured":"Hosono et al (2019) Role of a promoter mutation in TERT in malignant transformation of Pleomorphic Xanthoastrocytoma. World Neurosurg 126:624\u2013630. https:\/\/doi.org\/10.1016\/j.wneu.2018.12.095)","journal-title":"World Neurosurg"},{"key":"1531_CR35","doi-asserted-by":"publisher","unstructured":"Chengxin Ma et al (2018) BRAF V600E, TERT, and IDH2 mutations in Pleomorphic Xanthoastrocytoma: observations from a large case-series study. World Neurosurg. https:\/\/doi.org\/10.1016\/j.wneu.2018.09.050),","DOI":"10.1016\/j.wneu.2018.09.050"},{"issue":"6","key":"1531_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0156422","volume":"11","author":"L-N Lohkamp","year":"2016","unstructured":"Lohkamp L-N et al (2016) MGMT promoter methylation and BRAF V600E mutations are helpful markers to discriminate Pleomorphic Xanthoastrocytoma from giant cell glioblastoma. PLoS ONE 11(6):e0156422. https:\/\/doi.org\/10.1371\/journal.pone.0156422","journal-title":"PLoS ONE"}],"container-title":["La radiologia medica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11547-022-01531-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11547-022-01531-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11547-022-01531-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T09:02:31Z","timestamp":1664182951000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11547-022-01531-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,11]]},"references-count":36,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["1531"],"URL":"https:\/\/doi.org\/10.1007\/s11547-022-01531-3","relation":{},"ISSN":["1826-6983"],"issn-type":[{"value":"1826-6983","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,11]]},"assertion":[{"value":"7 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"thical approval was waived by the local Ethics Committee of University of Florence in view of the retrospective nature of the study and all the procedures being performed were part of routine care. The study was performed according to the Declaration of Helsinki and written informed consent was obtained for all patients. Research data are stored in an institutional repository and will be shared upon request with the corresponding author.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}